Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is du...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesplède, Thibault, Wainberg, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189025/
https://www.ncbi.nlm.nih.gov/pubmed/25166745
http://dx.doi.org/10.3390/v6093377
_version_ 1782338296445140992
author Mesplède, Thibault
Wainberg, Mark A.
author_facet Mesplède, Thibault
Wainberg, Mark A.
author_sort Mesplède, Thibault
collection PubMed
description Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication.
format Online
Article
Text
id pubmed-4189025
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-41890252014-10-08 Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy? Mesplède, Thibault Wainberg, Mark A. Viruses Review Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication. MDPI 2014-08-27 /pmc/articles/PMC4189025/ /pubmed/25166745 http://dx.doi.org/10.3390/v6093377 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Mesplède, Thibault
Wainberg, Mark A.
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
title Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
title_full Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
title_fullStr Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
title_full_unstemmed Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
title_short Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
title_sort is resistance to dolutegravir possible when this drug is used in first-line therapy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189025/
https://www.ncbi.nlm.nih.gov/pubmed/25166745
http://dx.doi.org/10.3390/v6093377
work_keys_str_mv AT mespledethibault isresistancetodolutegravirpossiblewhenthisdrugisusedinfirstlinetherapy
AT wainbergmarka isresistancetodolutegravirpossiblewhenthisdrugisusedinfirstlinetherapy

Ejemplares similares